Acyclovir has been widely used over the past decade as an effectiveand safe drug for the treatment of infections with herpes simplexvirus type 1 (HSV-1) and type 2 (HSV-2)1. Resistance to acyclovirwas initially noted only in studies of HSV infection in vitroand in animal models,2,3,4 then it was found in immunocompromisedpatients, and it has now become a well-documented clinical challengeto the care of patients infected with the human immunodeficiencyvirus (HIV)4,5,6,7,8,9,10,11,12. Acyclovir resistance has notbeen a problem to date in the treatment of immunocompetent peoplewith HSV infection. Although we identified . . . [Full Text of this Article]
Methods
Results
Case History
Laboratory Evaluation
Characterization of Virus Isolates
Discussion
Source Information
From the Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. (R.G.K., S.E.S.); the Division of Virology, Burroughs Wellcome Company, Research Triangle Park, N.C. (E.L.H.); and Chiron Corporation, Emeryville, Calif. (M.T.).
Address reprint requests to Dr. Straus at the Laboratory of Clinical Investigation, Bldg. 10, Rm. 11N228, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.
References
This article has been cited by other articles:
Wang, K., Mahalingam, G., Hoover, S. E., Mont, E. K., Holland, S. M., Cohen, J. I., Straus, S. E.
(2007). Diverse Herpes Simplex Virus Type 1 Thymidine Kinase Mutants in Individual Human Neurons and Ganglia. J. Virol.
81: 6817-6826
[Abstract][Full Text]
Danve-Szatanek, C., Aymard, M., Thouvenot, D., Morfin, F., Agius, G., Bertin, I., Billaudel, S., Chanzy, B., Coste-Burel, M., Finkielsztejn, L., Fleury, H., Hadou, T., Henquell, C., Lafeuille, H., Lafon, M. E., Le Faou, A., Legrand, M. C., Maille, L., Mengelle, C., Morand, P., Morinet, F., Nicand, E., Omar, S., Picard, B., Pozzetto, B., Puel, J., Raoult, D., Scieux, C., Segondy, M., Seigneurin, J. M., Teyssou, R., Zandotti, C.
(2004). Surveillance Network for Herpes Simplex Virus Resistance to Antiviral Drugs: 3-Year Follow-Up. J. Clin. Microbiol.
42: 242-249
[Abstract][Full Text]
Crumpacker, C. S.
(2004). Use of Antiviral Drugs to Prevent Herpesvirus Transmission. NEJM
350: 67-68
[Full Text]
Harris, W., Collins, P., Fenton, R. J., Snowden, W., Sowa, M., Darby, G.
(2003). Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovir. J. Gen. Virol.
84: 1393-1401
[Abstract][Full Text]
Grey, F., Sowa, M., Collins, P., Fenton, R. J., Harris, W., Snowden, W., Efstathiou, S., Darby, G.
(2003). Characterization of a neurovirulent aciclovir-resistant variant of herpes simplex virus. J. Gen. Virol.
84: 1403-1410
[Abstract][Full Text]
Griffiths, A., Chen, S.-H., Horsburgh, B. C., Coen, D. M.
(2003). Translational Compensation of a Frameshift Mutation Affecting Herpes Simplex Virus Thymidine Kinase Is Sufficient To Permit Reactivation from Latency. J. Virol.
77: 4703-4709
[Abstract][Full Text]
Chutkowski, C., Olson, B., McDonough, A., Mahoney, J., McSharry, J. J.
(2002). Use of a Single Monoclonal Antibody To Determine the Susceptibilities of Herpes Simplex Virus Type 1 and Type 2 Clinical Isolates to Acyclovir. CVI
9: 1379-1381
[Abstract][Full Text]
Bestman-Smith, J., Schmit, I., Papadopoulou, B., Boivin, G.
(2001). Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues. J. Virol.
75: 3105-3110
[Abstract][Full Text]
Lipsitch, M., Bacon, T. H., Leary, J. J., Antia, R., Levin, B. R.
(2000). Effects of Antiviral Usage on Transmission Dynamics of Herpes Simplex Virus Type 1 and on Antiviral Resistance: Predictions of Mathematical Models. Antimicrob. Agents Chemother.
44: 2824-2835
[Abstract][Full Text]
Suzutani, T., Saijo, M., Nagamine, M., Ogasawara, M., Azuma, M.
(2000). Rapid Phenotypic Characterization Method for Herpes Simplex Virus and Varicella-Zoster Virus Thymidine Kinases To Screen for Acyclovir-Resistant Viral Infection. J. Clin. Microbiol.
38: 1839-1844
[Abstract][Full Text]
Piret, J., Desormeaux, A., Gourde, P., Juhasz, J., Bergeron, M. G.
(2000). Efficacies of Topical Formulations of Foscarnet and Acyclovir and of 5-Percent Acyclovir Ointment (Zovirax) in a Murine Model of Cutaneous Herpes Simplex Virus Type 1 Infection. Antimicrob. Agents Chemother.
44: 30-38
[Abstract][Full Text]
Morfin, F., Thouvenot, D., De Turenne-Tessier, M., Lina, B., Aymard, M., Ooka, T.
(1999). Phenotypic and Genetic Characterization of Thymidine Kinase from Clinical Strains of Varicella-Zoster Virus Resistant to Acyclovir. Antimicrob. Agents Chemother.
43: 2412-2416
[Abstract][Full Text]
Tang, Y.-W., Mitchell, P. S., Espy, M. J., Smith, T. F., Persing, D. H.
(1999). Molecular Diagnosis of Herpes Simplex Virus Infections in the Central Nervous System. J. Clin. Microbiol.
37: 2127-2136
[Full Text]
Pillay, D., Zambon, M.
(1998). Antiviral drug resistance. BMJ
317: 660-662
[Full Text]
de la Iglesia, P., Melon, S., Lopez, B., Rodriguez, M., Blanco, M. I., Mellado, P., de Ona, M.
(1998). Rapid Screening Tests for Determining In Vitro Susceptibility of Herpes Simplex Virus Clinical Isolates. J. Clin. Microbiol.
36: 2389-2391
[Abstract][Full Text]
Christophers, J., Clayton, J., Craske, J., Ward, R., Collins, P., Trowbridge, M., Darby, G.
(1998). Survey of Resistance of Herpes Simplex Virus to Acyclovir in Northwest England. Antimicrob. Agents Chemother.
42: 868-872
[Abstract][Full Text]
Mertz, G. J., Loveless, M. O., Levin, M. J., Kraus, S. J., Fowler, S. L., Goade, D., Tyring, S. K.
(1997). Oral Famciclovir for Suppression of Recurrent Genital Herpes Simplex Virus Infection in Women: A Multicenter, Double-Blind, Placebo-Controlled Trial. Arch Intern Med
157: 343-349
[Abstract]
(1994). Acyclovir-resistant Genital Herpes in an Immunocompetent Man. Journal Watch Dermatology
1994: 1-1
[Full Text]
Previous
